Mizuho Securities USA LLC bought a new stake in shares of Drugs Made In America Acquisition Corp. (NASDAQ:DMAA - Free Report) in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 542,962 shares of the company's stock, valued at approximately $5,402,000. Mizuho Securities USA LLC owned about 1.86% of Drugs Made In America Acquisition at the end of the most recent reporting period.
Drugs Made In America Acquisition Stock Performance
Shares of DMAA stock traded up $0.03 during trading hours on Thursday, reaching $10.28. 878 shares of the stock traded hands, compared to its average volume of 101,970. Drugs Made In America Acquisition Corp. has a 1-year low of $9.95 and a 1-year high of $10.28.
About Drugs Made In America Acquisition
(
Free Report)
Drugs Made In America Acquisition Corp. is a blank check company newly incorporated in the Cayman Islands as an exempted company incorporated for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combination with one or more businesses.
Featured Stories
Before you consider Drugs Made In America Acquisition, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Drugs Made In America Acquisition wasn't on the list.
While Drugs Made In America Acquisition currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access